Background: Alzheimer's disease (AD) is a frequent form of senile dementia. Neuroglobin (Ngb) has a neuroprotective role and decreases Aβ peptide levels. Ngb, promoting Akt phosphorylation, activates cell survival involving cyclic-nucleotide response element-binding protein (CREB). A new molecule (IBU-LA) was synthetized and administered to an AD rat model to counteract AD progression. Objective: The aim of this study was to investigate the IBU-LA-mediated induction of Ngb neuroprotective and antiapoptotic activities. Methods: Brain morphology was analyzed through Bielschowsky staining, Aβ(1-40) and Ngb expression by immunohistochemistry. Akt, p-Akt, CREB and p-CREB expression was evaluated by Western blot, apoptosis through cytochrome C/Apaf 1 immunocomplex formation, and TUNEL analysis. Results: Bielschowsky staining and Aβ(1-40) expression show few nerve connections and Aβ(1-40) expression in an Aβ sample, preserved neuronal cells and Aβ(1-40) expression lowering in an IBU sample, mostly in IBU-LA. The Ngb level decreases in Aβ samples, compared to control and IBU-LA samples. p-Akt/Akt and p-CREB/CREB ratios reveal a reduction in Aβ sample, going back to the basal level in control and IBU-LA samples. Cytochrome C/Apaf 1 co-immunoprecipitate occurs and TUNEL-positive nuclei percentage decreases in Aβ sample. Probe test performance shows an increased spatial reference memory in the IBU-LA compared to the Aβ sample; no significant differences were seen between the IBU-LA and IBU samples. Conclusion: This evidence reveals that IBU-LA administration has the capability to maintain a high Ngb level allowing Ngb to perform a neuroprotective and antiapoptotic role, representing a valid tool in the therapeutic strategy of AD progression.

Keywords:
Neuroglobin, Akt, Cyclic-nucleotide response element-binding protein, Apoptosis, Alzheimer’s disease
1.
Selkoe DJ: Alzheimer's disease: a central role for amyloid. J Neuropathol Exp Neurol 1994;53:438-447.
2.
Parihar MS, Hemnani T: Alzheimer's disease pathogenesis and therapeutic interventions. J Clin Neurosci 2004;11:456-467.
3.
Richardson RL, Kim EM, Shephard RA, Gardiner T, Cleary J, O'Hare E: Behavioural and histopathological analyses of ibuprofen treatment on the effect of aggregated Abeta(1-42) injections in the rat. Brain Res 2002;954:1-10.
4.
Cerpa W, Dinamarca MC, Inestrosa NC: Structure-function implications in Alzheimer's disease: effect of Abeta oligomers at central synapses. Curr Alzheimer Res 2008;5:233-243.
5.
Retz W, Gsell W, Münch G, Rösler M, Riederer P: Free radicals in Alzheimer's disease. J Neural Transm Suppl 1998;54:221-236.
6.
Burmester T, Weich B, Reinhardt S, Hankeln T: A vertebrate globin expressed in the brain. Nature 2000;407:520-523.
7.
Kelsen J, Hundahl CA, Hay-Schmidt A: Neuroglobin: endogenous neuroprotectant or maintenance of homeostasis? Stroke 2008;39:e177-e178.
8.
Greenberg DA, Jin K, Khan AA: Neuroglobin: an endogenous neuroprotectant. Curr Opin Pharmacol 2008;8:20-24.
9.
Sun Y, Jin K, Mao XO, Xie L, Peel A, Childs JT, Logvinova A, Wang X, Greenberg DA: Effect of aging on neuroglobin expression in rodent brain. Neurobiol Aging 2005;26:275-278.
10.
Szymanski M, Wang R, Fallin MD, Bassett SS, Avramopoulos D: Neuroglobin and Alzheimer's dementia: genetic association and gene expression changes. Neurobiol Aging 2010;31:1835-42.
11.
Khan AA, Mao XO, Banwait S, Jin K, Greenberg DA: Neuroglobin attenuates beta-amyloid neurotoxicity in vitro and transgenic Alzheimer phenotype in vivo. Proc Natl Acad Sci USA 2007;104:19114-19119.
12.
Li RC, Pouranfar F, Lee SK, Morris MW, Wang Y, Goza, D: Neuroglobin protects PC12 cells against beta-amyloid-induced cell injury. Neurobiol Aging 2008;29:1815-1822.
13.
Chen LM, Xiong YS, Kong FL, Qu M, Wang Q, Chen XQ, Wang JZ, Zhu LQ: Neuroglobin attenuates Alzheimer-like tau hyperphosphorylation by activating Akt signaling. J Neurochem 2012;120:157-164.
14.
Nicholson KM, Anderson NG: The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 2002;14:381-395.
15.
Andreatta CP, Nahreini P, Hanson AJ, Prasad KN: Regulated expression of VP16CREB in neuroblastoma cells: analysis of differentiation and apoptosis. J Neurosci Res 2004;78:570-579.
16.
Cataldi A, di Giacomo V, Rapino M, Genovesi D, Rana RA: Cyclic nucleotide response element binding protein (CREB) activation promotes survival signal in human K562 erythroleukemia cells exposed to ionising radiation/etoposide combined treatment. J Radiat Res 2006;47:113-120.
17.
Cataldi A, di Giacomo V, Rapino M, Zara S, Rana RA: Ionizing radiation induces apoptotic signal through protein kinase C delta (delta) and survival signal through Akt and cyclic-nucleotide response element-binding protein (CREB) in Jurkat T cells. Biol Bull 2009;217:202-212.
18.
Bito H, Takemoto-Kimura S: Ca(2+)/CREB/CBP-dependent gene regulation: a shared mechanism critical in long-term synaptic plasticity and neuronal survival. Cell Calcium 2003;34:425-430.
19.
Pugazhenthi S, Wang M, Pham S, Sze CI, Eckman CB: Downregulation of CREB expression in Alzheimer's brain and in Aβ-treated rat hippocampal neurons. Mol Neurodegener 2011;19:60.
20.
DaRocha-Souto B, Coma M, Pérez-Nievas BG, Scotton TC, Siao M, Sánchez-Ferrer P, Hashimoto T, Fan Z, Hudry E, Barroeta I, Serenó L, Rodríguez M, Sánchez MB, Hyman BT, Gómez-Isla T: Activation of glycogen synthase kinase-3 beta mediates β-amyloid induced neuritic damage in Alzheimer's disease. Neurobiol Dis 2012;45:425-437.
21.
Klafki HW, Staufenbiel M, Kornhuber J, Wiltfang J: Therapeutic approaches to Alzheimer's disease. Brain 2006;129:2840-2855.
22.
Nordberg A: Mechanisms behind the neuroprotective actions of cholinesterase inhibitors in Alzheimer disease. Alzheimer Dis Assoc Disord 2006;20:S12-S18.
23.
Wu HM, Tzeng NS, Qian L, Wei SJ, Hu X, Chen SH, Rawls SM, Flood P, Hong JS, Lu RB: Novel neuroprotective mechanisms of memantine: increase in neurotrophic factor release from astroglia and anti-inflammation by preventing microglial activation. Neuropsychopharmacology 2009;34:2344-2357.
24.
Sozio P, D'Aurizio E, Iannitelli A, Cataldi A, Zara S, Cantalamessa F, Nasuti C, Di Stefano A: Ibuprofen and lipoic acid diamides as potential codrugs with neuroprotective activity. Arch Pharm 2010;343:133-142.
25.
Hirohata M, Ono K, Naiki H, Yamada M: Non-steroidal anti-inflammatory drugs have amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. Neuropharmacology 2005;49:1088-1099.
26.
Leuchtenberger S, Beher D, Weggen S: Selective modulation of Abeta-42 production in Alzheimer's disease: non-steroidal anti-inflammatory and beyond. Curr Pharm Des 2006;12:4337-4355.
27.
Miners JS, Baig S, Palmer J, Palmer LE, Kehoe PG, Love S: Aβ-degrading enzymes in Alzheimer's disease. Brain Pathol 2008;18:240-252.
28.
Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T, Kang DE, Marquez-Sterling N, Golde TE, Koo EH: A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 2001;8:212-216.
29.
Holmquist L, Stuchbury G, Berbaum K, Muscat S, Young S, Hager K, Engel J, Munch G: Lipoic acid as a novel treatment for Alzheimer's disease and related dementias. Pharmacol Ther 2007;113:154-164.
30.
Hager K, Kenklies M, McAfoose J, Engel J, Munch G: Alpha-lipoic acid as a new treatment option for Alzheimer's disease: a 48 months follow-up analysis. J Neural Transm Suppl 2007;72:189-193.
31.
Di Stefano A, Sozio P, Cerasa LS, Iannitelli A, Cataldi A, Zara S, Giorgioni G, Nasuti C: Ibuprofen and lipoic acid diamide as co-drug with neuroprotective activity: pharmacological properties and effects in beta-amyloid (1-40) infused Alzheimer's disease rat model. Int J Immunopathol Pharmacol 2010;23:589-599.
32.
Morris R: Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 1982;22:47-60.
33.
Dickson DW: Apoptotic mechanisms in Alzheimer neurofibrillary degeneration: cause or effect? J Clin Invest 2004;114:23-27.
34.
Chong ZZ, Li F, Maiese K: Activating Akt and the brain's resources to drive cellular survival and prevent inflammatory injury. Histol Histopathol 2005;20:299-315.
35.
Zara S, Di Stefano A, Nasuti C, Rapino M, Patruno A, Pesce M, Sozio P, Cerasa LS, Cataldi A: NOS-mediated morphological and molecular modifications in rats infused with Aβ(1-40), as a model of Alzheimer's disease, in response to a new lipophilic molecular combination codrug-1. Exp Gerontol 2011;46:273-281.
36.
Brittain T, Skommer J, Raychaudhuri S, Birch N: An antiapoptotic neuroprotective role for neuroglobin. Int J Mol Sci 2010;11:2306-2321.
37.
Fago A, Mathews AJ, Brittain T: A role for neuroglobin: resetting the trigger level for apoptosis in neuronal and retinal cells. IUBMB Life 2008;60:398-401.
38.
Raychaudhuri S, Skommer J, Henty K, Birch N, Brittain T: Neuroglobin protects nerve cells from apoptosis by inhibiting the intrinsic pathway of cell death. Apoptosis 2010;15:401-411.
39.
Chertkova RV, Sharonov GV, Feofanov AV, Bocharova OV, Latypov RF, Chernyak BV, Arseniev AS, Dolgikh DA, Kirpichnikov MP: Proapoptotic activity of cytochrome C in living cells: effect of K72 substitutions and species differences. Mol Cell Biochem 2008;314:85-93.
40.
Chen Q, Gong T, Liu J, Wang X, Fu H, Zhang Z: Synthesis, in vitro and in vivo characterization of glycosyl derivatives of ibuprofen as novel prodrugs for brain drug delivery. J Drug Target 2009;17:318-328.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.